Herbal medicines (Eunkyosan and Samsoeum) for treating the common cold: a protocol for a randomized, placebo-controlled, multicenter clinical trial

This study is a randomized, patient-assessor blind, controlled, parallel, and multicenter clinical trial. A total of 375 participants diagnosed with the common cold were enrolled via four hospitals. The common cold patients will take a daily dose of Eunkyosan or Samsoeum or a placebo, three times a day for eight days. The primary outcome is the change in total Wisconsin Upper Respiratory Symptom Scale-21-Korean (WURSS-21-K) score between baseline and six days. The secondary outcome includes the visual analogue scale (VAS). Safety is evaluated and adverse events are assessed throughout the trial. Written informed consent will be obtained from all study participants before enrollment.DiscussionThis results will be published in a peer-reviewed journal and disseminated in related conferences.Trial RegistrationClinicalTrials. gov, registration number: NCT04073511.
Source: Integrative Medicine Research - Category: Complementary Medicine Source Type: research

Related Links:

CORONAVIRUS is a contagious infection. There are nine UK confirmed cases thus far, and with people spluttering in public places likely due to a common cold, what's the best way to protect oneself? Is a face mask any use?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Basel, 10 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer ’s disease (AD). This form of AD, known as autosomal dominant AD (ADAD), accounts for less than 1% of all cases of the disease.1 The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with investigational medicine gantenerumab as measured by the novel DIAN Multivariate Co...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Abstract OBJECTIVE: As a post-approval commitment, this dose-ranging study was undertaken to evaluate efficacy and safety of onabotulinumtoxinA in adolescents. BACKGROUND: In adolescents, migraine is often undiagnosed or misdiagnosed and can present unique management challenges. OnabotulinumtoxinA was approved for prevention of chronic migraine (CM) in adults in 2010. METHODS: This multicenter, double-blind, parallel-group, randomized trial assessed a single treatment of onabotulinumtoxinA (155 U or 74 U) vs placebo (intramuscular saline) administered via the recommended fixed-dose fixed site p...
Source: Headache - Category: Neurology Authors: Tags: Headache Source Type: research
ConclusionsThis analysis confirms that treatment with intravenous reslizumab for more than 12 months is well tolerated in patients with asthma, with no evidence of rare safety events that were not detected in individual trials.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Basel, 06 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from the pivotal Part 2 of SUNFISH, a global placebo-controlled study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study showed that change from baseline in the primary endpoint of the Motor Function Measure scale (MFM-32)1 was significantly greater in people treated with risdiplam, compared to placebo (1.55 point mean difference; p=0.0156). The Revised Upper Limb Module (RULM),2 a key secondary endpoint, also showed an improvement (1.59 point difference; p=0.0028). Safety for risdi...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
It's too soon to know for sure how the tale of the novel coronavirus will play out,but at this point we have a pretty good idea. A stipulation in both of the scenarios at the linked essay is that yeah, it gets loose into the wild and eventually can show up anywhere in the world. I think that's pretty much definitely going to happen if it hasn't already.Scenario number 1, and most likely, in my view, it will just be one more virus that causes what amounts to a common cold and in a few people who are otherwise debilitated goes on to be complicated by pneumonia. In that case, for a year or two it will circulate as a novel vir...
Source: Stayin' Alive - Category: American Health Source Type: blogs
People wear face masks in the waiting area at China's Shenzhen Bao'an International Airport. Credit: UN News/Jing ZhangBy Fairuz AhmedNEW YORK, Feb 3 2020 (IPS) We are now living in a hyper communicative world where news does travel faster than lightning. Boundaries, borders, geographical and time differences have become next to obsolete in today’s speed driven world. At any point in time people, news and local occurrences can influence internationally without much local isolation. Along with the advantages of technology, communications and connections world is also facing new challenges that are proportionally evolv...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Asia-Pacific Economy & Trade Headlines Health Humanitarian Emergencies Population TerraViva United Nations Source Type: news
AbstractBackgroundThe combination ofLactobacillus plantarum HEAL9 andLactobacillus paracasei 8700:2 (commercially available as Probi Defendum®) has previously been reported to reduce the incidence, duration and severity of naturally acquired common colds in adults. The aim of the present study was to evaluate the impact of Probi Defendum® on aspects of common cold in healthy children 1 –6 years of age attending day care.MethodsA total of 131 children, out of the planned 320, were recruited into the study during 1 common cold season and randomised to consume once daily either 109 CFU (colony forming units...
Source: European Journal of Nutrition - Category: Nutrition Source Type: research
Many Americans likely grew a little nervous after the U.S. Centers for Disease Control and Prevention (CDC) announced Thursday that a novel coronavirus has spread for the first time within the U.S. But agency officials and other doctors have a simple message for Americans: keep doing what you’re doing to stay healthy. “The best things that you can do are the things that we generally recommend at this time of year to prevent the spread of infectious diseases,” Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, said during a Jan. 30 call with reporters. “W...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV public health Source Type: news
More than 8,000 people worldwide have been infected, and 171 have been killed, by a novel coronavirus that originated in Wuhan, China last month. But early research out of Wuhan suggests one group has been largely spared by the contagious disease: young children. A paper published in the New England Journal of Medicine on Thursday analyzed characteristics of 425 of the first people in Wuhan infected by the virus known as 2019-nCoV and found that none were younger than 15. The median age of patients was 59, and, at least as of mid-January, the youngest person to die from the disease was 36. Though there are not good data t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV Infectious Disease Source Type: news
More News: Clinical Trials | Common Cold | Complementary Medicine | Conferences | Eyes | Herbs | Hospitals | Respiratory Medicine | Study